You are here:

fosfomycin (Fomicyt)

Advice

following an abbreviated submission

fosfomycin (Fomicyt®) is accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of the following infections in adults and children including neonates:
- Acute osteomyelitis
- Complicated urinary tract infections
- Nosocomial lower respiratory tract infections
- Bacterial meningitis
- Bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Fosfomycin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.

Consideration should be given to national guidance on the appropriate use of antibacterial agents.

SMC restriction: initiation by microbiologists or infectious disease specialists.

Unlicensed preparations of intravenous fosfomycin are commonly used in the NHS in Scotland to treat multi-drug resistant gram negative organisms. This provides a licensed preparation. Estimated patient numbers are expected to be small.

Drug Details

Drug Name: fosfomycin (Fomicyt)
SMC Drug ID: 1033/15
Manufacturer: Nordic Pharma UK
Indication: For the treatment of the following infections in adults and children including neonates: - Acute osteomyelitis - Complicated urinary tract infections - Nosocomial lower respiratory tract infections - Bacterial meningitis - Bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
BNF Category:
Sub Category: 5.1 Antibacterial drugs
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 9 March 2015

Back